Pharmacological Effects of Benzodiazepines And Their Detection in The Forensic Laborator

Despite their limitations, benzodiazepines are still one of the most commonly used psychotropic medications in the world, especially in their role as anxiolytic, hypnotic, anticonvulsant, and muscle relaxant agents. Meanwhile, they are a common part of drug-facilitated crimes, a common factor in overdose deaths, especially when mixed with opioids, and they lack some of the unpleasant side effects of other drugs such as smell, taste, or amnestic effects. The current scientific literature regarding the pharmacology of commonly used benzodiazepines, their physiological and behavioural effects, how they contribute to overdose and polydrug deaths, and the changing analytical methods to detect benzodiazepines in forensic and clinical testing was reviewed and synthesized.

Mechanism of Action

The benzodiazepines are positive allosteric modulators of the GABA-A receptor, which is the main inhibitory neurotransmitter system in the CNS. The GABA-A receptor is a pentameric (five-subunit) ligand-gated chloride ion channel, with benzodiazepines binding to a regulatory site located at the interface between the α and γ subunits, which does not overlap with the GABA binding site. This binding does not directly open the chloride channel, but it is thought to interact with the receptor to shift its conformation, thereby increasing its sensitivity to binding with GABA, which in turn leads to increased chloride entry and hyperpolarization of the cell. As a consequence, the net effect of these drugs is a heightened inhibitory signal throughout the central nervous system, which accounts for the sedative, anxiolytic, and anticonvulsant effects for which these drugs are used.

Recent molecular studies have clarified this. Computational and structural analysis through molecular dynamics simulation and deep-learning-based modeling reveals that benzodiazepines and related “Z-drugs” create long-range allosteric communication between the extracellular GABA binding sites and the transmembrane domain of the channel to stabilize the open GABA-bound state of the channel and enhance the affinity of GABA for the receptor itself. Depending on the alpha subunits, different GABA-A receptor subtypes seem to produce different clinical effects; the alpha-1 containing receptors are associated with sedation and tolerance/dependence, and other receptor subtypes are more closely associated with anxiolytic action. This separation has inspired continued efforts for systematic and mechanistic study of the effects of the different subtypes in order to develop safer, less side-effect benzodiazepine alternatives.

Commonly Used Benzodiazepines and Clinical Effects

Benzodiazepines are usually classified according to elimination half-life due to the clinical indications and detection profile. Short-acting agents (e.g. midazolam, triazolam) are used in short-term sleep deprivation and procedural sedation; intermediate-acting agents (e.g. alprazolam, lorazepam) are often used in anxiety disorders and panic disorder; and long-acting agents (e.g. diazepam, clonazepam) are used in seizure disorders, muscle spasms, and alcohol withdrawal management, due to their slower onset and offset of effect.

From a clinical perspective, the effects of benzodiazepines occur along a dose-dependent continuum, with lower doses leading to decreased anxiety and muscle tension, moderate doses to sedation and anterograde amnesia, and higher doses causing severe psychomotor and respiratory depression, psychomotor disinhibition, and loss of consciousness. That is why this combination of effects — anxiolytic, hypnotic, anticonvulsant, and myorelaxant — is so broad, is so desirable, and is what makes these drugs so easy to misuse once a tolerance develops, and greater doses are desired to have the same effect as before.

Addiction, dependence and misuse

There is well-established evidence of tolerance and physical dependence with chronic benzodiazepine use. Likewise, this can be shown to occur through modulation of benzodiazepine binding sites on GABA-A receptors, the uncoupling of the allosteric relationship between the benzodiazepine binding site and the GABA binding site, and alterations in receptor subunit turnover. Uncoupling in particular is believed to account for decreased clinical effectiveness observed in patients after prolonged use, because the benzodiazepine site remains occupied by the drug, but is unable to send an effective allosteric signal to the receptor.

Benzodiazepines are widespread drugs with their benefits being increasingly outweighed by the drawbacks of benzodiazepine use disorder, according to a recent expert review, which outlines pharmacology, clinical indications, and misuse patterns, and consequently suggests preventive strategies and therapeutic approaches specifically geared towards the neuroadaptive changes that underlie dependence. This is an escalating clinical issue because tolerance to the receptors can occur at some level, regardless of the fact that benzodiazepines are used extensively as prescribed and not necessarily in an overtly “misused” manner.

Risk of overdose and polydrug use

Benzodiazepines are not often lethal if used alone, but their toxicity increases significantly when mixed with other drugs of the central nervous system, particularly opioids. A narrative review of benzodiazepine use in the context of opioid use disorder (OUD) revealed that dual use is common, and that emergency department visits and opioid-benzodiazepine overdose deaths have risen at a significantly higher rate than single-use opioid overdose deaths over the past few years, with benzodiazepine and opioid use disorder being a strong risk factor for opioid overdose. The same review found that people taking an opioid along with a benzodiazepine had almost 15 times as much risk of drug-related death as those taking neither medication, and that long-term use of high doses of benzodiazepines alone raises the risk of death by 70 to 80%.

This risk is exacerbated by the physiological effects of the drugs on the lungs (and the heart): when taken together, benzodiazepines and opioids have an additive effect on heart rate and respiratory drive, greatly increasing overdose risk. A qualitative study of individuals who co-use benzodiazepines, also known as “z-drugs,” and opioids found there were six patterns of co-use, from controlled daily use to uncontrolled binge-type use, and among those who co-used, the least controlled, binge-type pattern was associated with the highest number of near-fatal and non-fatal overdose experiences. The same study found some people intentionally combine the two classes of drugs as a means to self-manage and minimize their own risk of drug-related death, even though this is often a counterproductive approach to drug use. 

Designer Benzodiazepines and detection challenges

One particular worry is the creation of “designer” or “novel” benzodiazepines that are chemically similar to the original drugs, but slightly altered to have a desired effect or to evade the laws and regulations currently in place. These designer versions are not as well characterized as their pharmaceutical relatives and have not undergone formal clinical testing to a large extent; thus, the safety profile of these variants is not well understood. A review article specific to this new, rapidly expanding class of drugs points out that detection of these drugs is not just a problem in forensic toxicology, but also in therapeutic drug monitoring and anti-doping sports testing.

This detection issue is important because more recent “designer” benzodiazepines are frequently not reliably detected by standard toxicology screens based on immunoassays, which are still widely used as a first-line test. They can also give false negative and false positive results in antibody tests developed for the original compounds. This is where the chromatography coupled to mass spectrometry (MS) technique has come into its own in the last 20 years, providing the benefit of sensitivity and specificity to differentiate individual benzodiazepines and metabolites from each other, which has superseded older methods relying solely on immunoassays.

The difficulty of a dedicated review of benzodiazepine-related drug-facilitated crime is compounded by the fact that they are rapidly metabolised, induce significant amnestic effects which make it difficult for victims to provide evidence, and in different jurisdictions, legal definitions of consent vary. Such a dual effect of pharmacological amnesia and analytical detection challenges is known as a central hurdle in clinical detection and effective prosecution of benzodiazepine drug-facilitated crime scenarios.

Improvements in analytical methods

The high sensitivity and ability to identify individual compounds and metabolites that are not distinguishable by immunoassays make liquid chromatography-tandem mass spectrometry the gold standard for definitive benzodiazepine detection. Forensic toxicology reviews current detection periods, which range widely from blood and urine (short-term, reflecting recent use, particularly important in the investigation of acute drug-facilitated crimes), to hair (longer-term, reflecting drug exposure over weeks/months and can be segmented to provide a general timeline of use, but has limitations of external contamination and cosmetic treatment effects that may alter the appearance of the hair and affect interpretation).

Gas chromatography-mass spectrometry is still a complementary, affordable platform. Innovation in GC-MS methodology has tracked the fast-changing landscape of designer drugs in recent years and continues to the present day, with a review of novel psychoactive substance detection methods from 2020 to 2025 showing that as designer drugs have evolved, novel procedures for specific derivatization have also been introduced to accommodate the analysis of structurally unusual designer benzodiazepines that fail to chromatograph as expected. Drug chemistry continues to evolve in clandestine drug production, as outlined in the same review, which identified designer benzodiazepines as one of the major groups of novel psychoactive substances (NPSs) found in forensic cases, along with designer opioids, synthetic cathinones, and synthetic cannabinoids.

In the future, electrochemical nanosensors have shown promise as a new technology for on-site detection, while at present, mass spectrometry-based techniques are the standard “gold standard” method. It could be useful in the medical field to have such a tool to help improve timely testing in acute clinical and forensic situations where designer substances can get metabolised very quickly before the sample gets to the testing station.

Synthesis

Combined, this literature portrays benzodiazepines as a well-studied, rapidly moving issue that presents a challenge to practice. The efficacy of their binding to the GABA-A receptor is beginning to be defined at a molecular level, and may be translated to a more specific and safer drug action of the GABA-A receptors in the future. Clinically, their risk profile is not their own alone, but rather, when they are combined with other depressants (specifically opioids), the combination results in respiratory depression, which accounts for a disproportionate amount of overdose deaths, and often in identifiable patterns of co-use behaviour. Chemically, the field is constantly running to catch up with yet another generation of designer benzodiazepines that are not frequently captured in immunoassay screens and are increasingly appearing in the field, while confirmatory testing is dependent on the laboratory use of mass-spectrometry-based techniques, and the adoption of quicker point-of-care (POC) testing is still under way.

Conclusion

In the modern era of pharmacology and forensic science benzodiazepines are both essential drugs and a constant threat of inappropriate use, overdose, and facilitation of crime. Future clinical relevance will require greater knowledge of receptor-subtype pharmacology to decrease dependency risk, and the ability to respond effectively as a forensic and public-health response will depend on maintaining the ability to detect the compounds, especially designer analogs that are continually being created.

References:

1. Benzodiazepine Dependence: Clinical and Molecular Aspects, Preventive Strategies and Therapeutic Approaches. (2026). International Journal of Molecular Sciences, 27(3), 1430. https://www.mdpi.com/1422-0067/27/3/1430
2. Benzodiazepine Use Among Individuals with Opioid Use Disorder: A Narrative Review. (2025). Substance Abuse and Rehabilitation, 16, 283–291. https://www.dovepress.com/article/download/108050
3. Emerging Novel Psychoactive Substances (2020–2025): GC-MS Approaches for Separation, Detection, and Characterization. (2025). Chemosensors, 13(12), 426. https://www.mdpi.com/2227-9040/13/12/426
4. Engin, E. (2023). GABA A receptor subtypes and benzodiazepine use, misuse, and abuse. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2022.1060949
5. Forensic toxicology of benzodiazepines: neuropharmacological effects, analytical challenges, and emerging detection strategies. (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12507772/
6. Molecular Mechanisms and Probe-Dependent Effects of Clinically Relevant GABAA Receptor Modulators. (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC13330556/
7. Qualitative study of Benzodiazepine/Z-drug and Opioid Co-Use Patterns and Overdose Risk. (2024). medRxiv. https://www.medrxiv.org/content/10.1101/2024.07.26.24311053v2.full.pdf
8. Recent findings and advancements in the detection of designer benzodiazepines: a brief review. (2023). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10750316/